Abstract:Despite the progress made with the recent clinical use of the anticancer compound cabazitaxel, the efficacy in patients remains unsatisfactory, largely due to the high in vivo toxicity of the agent. Therefore, strategies that achieve favorable outcomes and good safety profiles will greatly expand the repertoire of this potent agent. Here, we propose a combinatorial strategy to reform the cabazitaxel agent and the use of sequential supramolecular nanoassembly with liposomal compositions to assemble a prodrug-formulated liposome, termed lipoprodrug, for safe and effective drug delivery. Reconstructing cabazitaxel with a polyunsaturated fatty acid (i.e., docosahexaenoic acid) via a hydrolyzable ester bond confers the generated prodrug with the ability to be readily integrated into the lipid bilayer of liposomes for systemic administration. The resulting lipoprodrug scaffold showed significantly sustained drug release profiles and improved pharmacokinetics in rats as well as a reduction in systemic toxicity in vivo. Notably, the lipoprodrug outperformed free cabazitaxel in terms of in vivo therapeutic efficacy in multiple separate tumor xenograft-bearing mouse models, one of which was a patient-derived xenograft model. Surprisingly, the lipoprodrug was able to reduce tumor invasiveness and reprogram the tumor immunosuppressive microenvironment by proinflammatory macrophage polarization. Our findings validate this lipoprodrug approach as a simple yet effective strategy for transforming the highly toxic cabazitaxel agent into an efficacious nanomedicine with excellent in vivo tolerability. This approach could also be applied to rescue other drugs or drug candidates that have failed in clinical trials due to poor pharmacokinetic properties or unacceptable toxicity in patients.

Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.

A Vascular Disrupting Agent Overcomes Tumor Multidrug Resistance by Skewing Macrophage Polarity Toward the M1 Phenotype.

Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment.

Vascular disrupting agent-induced amplification of tumor targeting and prodrug activation boosts anti-tumor efficacy

Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI

Targeting FAPα-expressing Hepatic Stellate Cells Overcomes Resistance to Antiangiogenics in Colorectal Cancer Liver Metastasis Models.

A self-activating nanoized vascular disrupting agent for selective anti-tumor therapy

Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts.

Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy

Selective Eradication of Tumor Vascular Pericytes by Peptide-Conjugated Nanoparticles for Antiangiogenic Therapy of Melanoma Lung Metastasis.

Spatiotemporally Targeted Nanomedicine Overcomes Hypoxia-Induced Drug Resistance of Tumor Cells after Disrupting Neovasculature.

Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect

Modulation of pericytes by a fusion protein comprising of a PDGFRβ-antagonistic affibody and TNFα induces tumor vessel normalization and improves chemotherapy

Enhanced Anti-Tumor Efficiency of Gemcitabine Prodrug by FAPα-mediated Activation.

Targeting Pericytes with a PDGF-B Aptamer in Human Ovarian Carcinoma Models

Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy

Tumor Resistance to Vascular Disrupting Agents: Mechanisms, Imaging, and Solutions.

Evaluation Of The Tumor Targeting Of A Fap Alpha-Based Doxorubicin Prodrug

Mechanisms of Tumor Resistance to Small-Molecule Vascular Disrupting Agents: Treatment and Rationale of Combination Therapy

Co-delivery of Plinabulin and Tirapazamine boosts anti-tumor efficacy by simultaneously destroying tumor blood vessels and killing tumor cells

Evaluation of the Tumor Targeting of a FAPα-based Doxorubicin Prodrug